Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of safety and clinical tolerability of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients.

Next Previous
X
Search
Trial Profile

Assessment of safety and clinical tolerability of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Adverse reactions
  • Sponsors ASIT biotech; DMS Imaging

    • Most Recent Events

    • 22 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 24 Jan 2017 Results published in an ASIT biotech media release.
    • 24 Jan 2017 According to an ASIT biotech media release, the last patient has attended the last visit of the trial thereby completing the clinical phase of the trial. The clinical data is currently being verified and publication of results is anticipated before the end of the first quarter of 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top